

Basic and Translational SCIENTIFIC MEETING

May 15-17, 2024 • Washington, DC

Preliminary Programme

Day 1: Wednesday, May 15

Topic: Chronic Graft vs Host Disease	
Session Chair: Bruce Blazar, MD; University of Minnesota, US	
8:00 – 8:15 AM (15 mins)	Welcome and Introduction
8:15 – 8:45 AM (30 mins)	Distinct brain chronic GVHD pathophysiology highlights the need for organ-specific targeted therapeutics Kelli MacDonald, PhD; QIMR Berghofer Medical Research Institute, AU
8:45 – 9:15 AM (30 mins)	Chronic GVHD; Current Challenges in Translating Our Pathophysiology Knowledge into Clinical Practice Gerard Socié, MD, PhD; Hôpital Saint-Louis; FR
9:15 – 9:45 AM (30 mins)	Targeting Pathways that Drive B Cell Fate and Function after HCT Stefanie Sarantopoulos, MD, PhD; Duke University, US
9:45 – 10:00 AM (15 mins)	Abstract 1: Absence of MHC Class I Expression on Target Cells Exacerbates CD4+ T Cell Mediated Killing Emma Lauder, BA; University of Michigan, US
10:00 – 10:30 AM (30 mins)	Break
Topic: Genome Editing	
Session Chair: Chiara Bonini, MD; IRCCS Ospedale San Raffaele, IT	
10:30 – 11:00 AM (30 mins)	TCR and Inhibitory receptor gene editing for cancer immunotherapy Chiara Bonini, MD; IRCCS Ospedale San Raffaele, IT
11:00 – 11:30 AM (30 mins)	Advanced TCR Engineering for Repertoire Analysis and Adoptive T Cell Therapy Dirk Busch, MD; Technische Universität München, DE
11:30 – 12:00 PM (30 mins)	Base Edited CAR T Cells for Acute Leukemia Waseem Qasim, MD; University College London, UK
12:00 – 12:15 PM (15 mins)	Abstracts 2: Cytosine Base Editor Ameliorates the Safety Profile of TCR Edited T Cells for the Adoptive Cell Therapy of Gastrointestinal Tumors Martina Spiga, PhD; San Raffaele Scientific Institute, IT
12:15 – 5:00 PM	Lunch and Afternoon Networking
5:00 – 6:00 PM	Poster Tour + Networking Hour
6:00 – 7:30 PM	Allogeneic Hematopoietic Cell Transplantation in Seattle as an Example of Intensive Bench-to-Bedside Research Rainer Storb, MD; Fred Hutchinson Cancer Center, US

Day 2: Thursday, May 16

Topic: Cell Engineering Session Chair: Carl June, MD; University of Pennsylvania, US	
8:00 – 8:30 AM (30 mins)	Applying Genome Engineering to Enhance CAR T cells Carl June, MD; University of Pennsylvania, US
8:30 – 9:00 AM (30 mins)	Novel Ways to Metabolically Rewire T Cells for Adoptive Immunotherapy Chrystal Paulos, PhD; Winship Cancer Institute, US
9:00 – 9:30 AM (30 mins)	Advancing Novel Cellular Immunotherapies for Solid Tumors: Clinical Trials and Tribulations, and a Bright Future Saul J. Priceman, PhD; City of Hope, US
9:30 – 9:45 AM	Abstract 3: Human OX40I-Car-Tregs Target Activated Antigen-Presenting Cells and Effectively Control T Cell Alloreactivity, PhD Xianliang Rui PhD; Boston Children's Hospital, US
9:45 – 10:15 AM (30 mins)	Break
Topic: Malignant and Non-malignant Hematopoiesis Session Chair: Pavan Reddy, MD; Baylor College of Medicine, US	
10:15 – 10:45 AM (30 mins)	Epigenetic Regulators in Clonal Hematopoiesis Margaret (Peggy) Goodell, PhD; Baylor College of Medicine, US
10:45 – 11:15 AM	Decoding Human Hematopoietic Stem Cell Self-Renewal Hanna Mikkola, MD, PhD; University of California Los Angeles, US
11:15 – 11:45 AM	Regulation of Hematopoietic Stem Cell Dormancy Nina Cabezas Wallscheid, PhD; Max-Planck-Institute of Immunobiology and Epigenetics, DE
11:45 – 12:00 PM (15 mins)	Abstracts 4: : Combined TCR-Seq and Multiparameter Flow Cytometry Reveal a T-Cell Bottleneck and Delayed Tnaive Reconstitution After Post-Transplant Cyclophosphamide With Implications for Efficacy and Toxicity: Results of the BMT-CTN 1801 Study Susan Ehrenkranz de Wolf, MD; Memorial Sloan Kettering Cancer Center
12:00 – 5:00 PM	Lunch and Afternoon Networking
5:00 – 6:00 PM	Meet-the-Professor Session
6:00 – 7:30 PM	HLA in Cellular Therapy: Past, Present and Future Katharina Fleischhauer, MD; Institute for Experimental Cellular Therapy/University Hospital Essen, DE

Connecting Basic, Translational and Clinical Science

3rd JOINT **ASTCT** + **EBMT**

Basic and Translational **SCIENTIFIC MEETING**

May 15-17, 2024 • Washington, DC

ASTCT®

EBMT

Preliminary Programme

Day 3: Friday, May 17

Topic: Biology of Relapse	
Session Chair: Nicolaus Kröger, MD; University Hospital Hamburg-Eppendorf, DE	
8:00 – 8:30 AM (30 mins)	Toward the Development of Synthetic Immunity to Cancer Kole Roybal, PhD; University of California, San Francisco, US
8:30 – 9:00 AM (30 mins)	Using Marrow Infiltrating T cells to Treat Relapse Post HSCT with PTCy Leonido Luznik, MD; Johns Hopkins University, US
9:00 – 9:30 AM (30 mins)	Azacytidine and AML: It All Goes Back to Globin Timothy Ley, MD; Washington University School of Medicine, US
9:30 – 9:45 AM (15 mins)	Abstract 5: Terminally Exhausted CD8 T Cells Maintain Functional Capacity After Stem Cell Transplantation or Car T Cell Therapy for Hematological Malignancies Simone Minnie, PhD; Fred Hutchinson Cancer Center, US
9:45 – 10:00 AM (15 mins)	Closing remarks